Activating HER3 mutations in breast cancer.

ABSTRACT: Recent studies have highlighted a role of HER3 in ER and HER2-driven breast cancers. We sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast cancer cells using ectopic expression of HER3 mutants. We found that HER3^T355I mutant is activating with increased cell proliferation in ER+ T47D and MCF-7 breast cancer cells lacking HER2 over-expression. Immunoblotting and receptor tyrosine kinase array results indicated that T47D and MCF-7 cells expressing HER3^T355I had increased p-HER4 and p-HER1 expression. Our data showed that HER3^T355I induced cell proliferation is via HER4/HER1-dependent ERK1/2 and cyclinD1 mediated pathways in ER+ cells. ERα expression is upregulated in ER+ cells expressing HER3^T355I mutant. We no

SUBMITTER: Mishra R 

PROVIDER: S-EPMC6021238 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature